Emcure Pharmaceuticals IPO: The mainboard initial public offering (IPO) of leading pharma major Emcure Pharmaceuticals Ltd will open for subscription on Wednesday, July 3, 2024. The company develops, manufactures, and markets a wide range of pharmaceutical products across several major therapeutic areas. Emcure Pharma’s product portfolio consists of injectables, biotherapeutics, and orals. The research and development (R&D)-driven firm has targeted markets in over 70 countries, with a significant presence in Europe, Canada, and India.
The selling shareholders in the public issue include promoters Satish Ramanlal Mehta, Sunil Rajanikant Mehta, Namita Vikas Thapar, Samit Satish Mehta, and investor BC Investments IV Ltd, an affiliate of US-based private equity major Bain Capital. Between March 31, 2024, and March 31, 2023, Emcure Pharma’s profit after tax (PAT) decreased 6.1 per cent while its sales rose 11.33 per cent.
According to the red herring prospectus (RHP), the company’s listed peers are Dr. Reddy’s Laboratories Ltd (with a P/E of 17.93), Cipla Ltd (with a P/E of 30.10), Alkem Laboratories Ltd (with a P/E of 33.86), Torrent Pharmaceutical Ltd (with a P/E of 57.74), Mankind Pharma (with a P/E of 45.30), Abbott India Ltd (with a P/E of 47.43), J. B. Chemicals & Pharmaceutical Ltd (with a P/E of 50.49).
